Introduction
September 2014 saw a major advance in transplantation following the birth of a child from a mother who had received a successful uterus allotransplantation at the University of Gothenburg, Sweden, by Br€ annstr€ om et al (1, 2) . Uterus transplantation is a form of vascularized composite allograft transplantation, which is the transplantation of multiple tissues (e.g. muscles, nerves, skin) combined into a functional unit. Many elements of uterus transplantation are unique compared with other vascularized composite allograft types (e.g. face or hand transplantation) because (a) uterus transplantation can be performed from both deceased donors and living donors; (b) it is a temporary transplantation; (c) it is not life-saving, although it may enhance quality of life for both parents; (d) its success is determined many months to years after its implantation; (e) its living donors renounce an organ for transplantation after it has exhausted its function in the donor; and (f) the transplanted organ is shared by two people (mother and baby).
Candidates for uterus transplantation are those affected by a congenital absence or malformation of the uterus (e.g. Mayer-Rokitansky-K€ uster-Hauser syndrome), acquired dysfunction of the uterus (e.g. irreversible intrauterine adhesions, radiation damage, inoperable fibromas), or loss of the uterus either from benign or malignant pathologies or from postpartum complications. Current options include adoption and surrogate pregnancies, and although both are valid alternatives, neither provides the women affected by absolute uterine infertility (AUI) the possibility to experience and carry a pregnancy (3, 4) . It is this wish that inspires women to pursue uterus transplantation, which ultimately means undertaking risks from immunosuppression, a high-risk pregnancy, and at least three surgical procedures, including the initial allotransplantation, caesarian section to deliver the child (and a second section if a second child is desired), and a graft hysterectomy after the delivery.
Uterus transplantation has several clearly defined steps:
1 Successful transplantation of the uterus allograft, as defined by adequate vascular perfusion and the presence of vital tissue on the baseline cervical biopsy 2 Normal menstrual cycle, marking a proper uterine response to the hormonal milieu 3 Stable immunosuppression 4 Successful implantation of a fertilized ovum 5 Pregnancy 6 Delivery of a healthy child Failure can plague any of these individual steps.
Baylor University Medical Center at Dallas initiated an institutional review board (IRB)-approved experimental pilot program for uterus transplantation (IRB no. 015-158, "Uterus Transplant and Pregnancy in Women Affected by Absolute Uterine Infertility") designed for up to 10 uterus transplantations from either live or deceased donors in women affected by AUI. In preparation for these first transplants, two members of the team (G.T. and C.K.) performed five deceased donor hysterectomies and witnessed one living donor uterus transplant. Most important, two members of the original team for the University of Gothenburg (M.O. and L.J.) actively participated in all phases of selection, surgery, and follow-up of all five living donor uterus transplants described in this paper. The decision to start with living instead of deceased donors was multifactorial: (a) The only live births have occurred after living donor uterus transplantation; (b) the unknown of past medical and social events and the potential for gynecological pathologies are practically eliminated with living donors, thanks to their more thorough workup; and (c) the logistics of living donation allowed better planning for the two non-US members of the team. We recognize that the follow-up is short for the recipients described in this paper and limited to the initiation of regular menstrual cycles; however, the observations pertinent to donor selection, evaluation, surgical technique, and immediate postoperative follow-up made it possible to have two recipients with uneventful courses and functioning uteri. We believe that these observations will build on the knowledge in this evolving field and be of great value to colleagues who are in the process of initiating a uterus transplant program.
Materials and Methods
The protocol was submitted in June 2015 and approved in November 2015. The study is registered as a clinical trial at ClinicalTrials.gov (identifier NCT02656550). The inclusion and exclusion criteria for both donors and recipients are shown in Table 1 .
All living donor candidates were nondirected, and the donor acceptance criteria, postoperative care, and follow-up were derived from established guidelines of the United Network for Organ Sharing for nondirected kidney and liver donations (5) . All donors had prior successful pregnancies and underwent a thorough evaluation process. The evaluation process for both donors and recipients, described in Table 2 , closely resembled that used by the University of Gothenburg, with particular attention given to the psychological evaluation and well-being of both donors and recipients, thanks to the support of an experienced psychologist who also consulted with the psychology team from Gothenburg. Candidate selection, donor and recipient surgeries, and immediate follow-up were conducted with the consultation and collaboration of members of the team from the University of Gothenburg (M.O. and L.J.).
The donors were evaluated and closely followed by the donor advocate team of the Simmons Transplant Institute at Baylor University Medical Center. The experimental nature of the trial was explained to all candidates. Known risks and complications of abdominal hysterectomy, data derived from the Swedish experience, and data derived from the transplant literature regarding side effects of immunosuppression, risks during pregnancy, and risks to the child were used to obtain informed consent. The candidates were presented to and approved by all members of a multidisciplinary team, mimicking the established practice for any other solid organ transplantation.
The donor operation is more extensive than a simple hysterectomy because the vascular pedicles of the uterus must be dissected completely to allow acceptable graft inflow and outflow. The living donor hysterectomy was performed through an infraumbilical midline incision with the donor in the supine position. The arterial vascular pedicle of the graft was the uterine artery in conjunction with a patch or segment of internal iliac artery. The venous outflow of the graft was the uterine vein and/or the utero-ovarian veins (the section of the ovarian vein between the uterus and the ovary). The uterus was transected below the cervix, obtaining a cuff sufficient for a safe anastomosis to the recipient's vagina. Following removal, the uterus was flushed on the back table with KPS solution (Organ Recovery Systems Inc., Itasca, IL) in the first four donors and with HTK (Custodiol HTK; Essential Pharmaceuticals, LLC, Ewing, NJ) in the fifth donor via an angiocath placed in the arterial inflow and connected to a 20-mL syringe. When necessary, arterial reconstruction was performed using microvascular surgical techniques.
The recipient operation was performed through a midline infraumbilical incision with the recipient in the lithotomy position. The external iliac artery and vein were dissected completely along their length bilaterally. The arterial anastomosis was performed using the internal iliac artery patch of the donor graft to the external iliac artery of the recipient using 7-0 Prolene (Ethicon, Somerville, NJ) sutures. The vein anastomosis used the best venous outflow present in the donor graft (either the uterine or utero-ovarian vein, as judged by inspection on the back table) using 7-0 Prolene sutures to anastomose to the external iliac vein of the recipient. Following reperfusion of the allograft, the cervix of the donor uterus was anastomosed to the recipient vaginal vault using interrupted O Vicryl (Ethicon) sutures. A Cook Doppler flow-monitoring probe (Cook Medical, Bloomington, IN) was placed on one of the donor uterine arteries to monitor arterial flow.
Postoperatively, the patient recovered in the intensive care unit before being transferred to a regular transplant surgical floor. In the first four recipients, daily intravaginal Doppler ultrasounds were performed for the first 5 days after transplant, and a graft cervical biopsy was performed on the fifth postoperative day. In the fifth recipient, the ultrasound was performed only transabdominally. As part of the modifications to our follow-up, two tests were performed that were not part of the initial protocol design: magnetic resonance imaging (MRI) of the uterus to assess perfusion and an examination under anesthesia to better visualize the cervix.
Recipient immunosuppression involved induction with thymoglobulin (1.5 mg/kg intravenously every 2 days 93) and maintenance immunosuppression using the calcineurin inhibitor tacrolimus (0.2 mg/kg orally daily, initial trough 7-12 ng/mL), mycophenolic acid (720 mg orally twice a day), and a rapid steroid taper over 49 days. Protocol cervical biopsies were performed in the last two recipients: once a week for the first month after transplant and every 2 weeks thereafter.
Results
To date, five living donor uterus transplants have been performed at Baylor University Medical Center. The follow-up for the two successful grafts is 6 and 3 mo, respectively. Candidate characteristics are shown in Tables 3 and 4 .
Donors
Outcomes: The donors' perioperative course is summarized in Table 5 . The mean operative time for the donor hysterectomy was 330 min, with the majority of that time spent on dissection of the uterine veins. Care was taken during this dissection to avoid ureteral injury, as the ureter crosses the space between the vascular pedicle and the body of the uterus as it enters the bladder. Dissection of the iliac vein at the point of inflow of the uterine vein was laborious, whereas dissection of the uterine artery proved simpler, given its more accessible and superficial plane at its division from the internal iliac artery. In the initial two donors, 01-D and 02-D, the vessels were clamped prior to uterus transection, whereas in the latter three donors, the practice was reversed. The allograft was flushed with KPS/HTK solution via the uterine arteries on the back Observations and lessons learned: Preoperative imaging and vessel assessment: A computed tomography (CT) angiogram was accurate in defining arterial inflow preoperatively but was insufficient in defining the venous diameter and length. Although the vein may appear acceptable near the uterine body, it may taper to a group of threadlike tributaries near the internal iliac vein confluence. Because uterine vein dissection was the lion's share of the donor hysterectomy, and because venous outflow was identified as a pitfall from our experience, improved preoperative imaging was paramount. In hindsight, MRI with venous phase represents a superior modality for defining the uterine veins.
The uterine artery diameter is 1-2 mm. Although it may be technically feasible for an end-to-side anastomosis to the external iliac artery in the recipient, procuring an additional partial or entire segment of donor internal iliac artery for a patch simplifies that anastomosis and may decrease the thrombosis risk. Procuring this donor internal iliac segment interrupts flow to the anterior division of the internal iliac artery in the donor; however, only one of the donors had transient symptoms attributed to arterial insufficiency, manifesting as pain in the gluteal area after exertion, likely because collateral circulation from the posterior division of the internal iliac artery mitigates the issue over the long term (6). We encountered a severely diseased orifice of the uterine artery at the internal iliac artery in the oldest donor, 02-D, which made cannulation for back-table flush through the patch impossible. The solution was a transection of the uterine artery distal to the takeoff from the internal iliac artery, direct cannulation of the uterine artery with a 24-gauge angiocath for flushing, and backtable microvascular reconstruction of the uterine artery and internal iliac artery patch (Figure 1 ). This reconstruction was accomplished by end-to-end anastomosis of the uterine artery to the stump of the obturator or internal pudendal artery, still in continuity with the original internal iliac segment of the donor and free of disease to recreate the patch for an easier recipient external iliac artery anastomosis.
There was significant variation in the quality of the donor uterine arterial vasculature that was not readily apparent on preoperative imaging. Despite imaging showing patent uterine arteries, pathological analysis of the three American Journal of Transplantation 2017; 17: 2901-2910failed uterus allografts ultimately revealed severe arterial disease from intimal hyperplasia in the oldest donor, as well as significant disease in the arteries of the other two failed allografts (Figure 2 ).
Vaginal transection: Initially, the rationale for transecting the donor uterus following clamping of the vessels was to allow more space and mobility of the uterus for the transection and to minimize bleeding. This sequence was reversed in the latter two donors when it became evident that transection of the uterus made placement of vascular clamps easier, did not lead to excessive bleeding, and shortened warm ischemia time.
Recipients
Perioperative details are summarized in Table 6 . All recipients had Mayer-Rokitansky-K€ uster-Hauser syndrome, and all had their eggs retrieved and fertilized prior to uterus transplant.
For the implantation, the uterine arterial anastomosis for the first two recipients (01-R and 02-R) used a patch of donor internal iliac artery end-to-side to the recipient external iliac artery. In the latter three recipients, the arterial anastomosis was performed using a whole segment of the donor iliac artery. For the venous outflow of the uterine graft, the first three recipients (01-R, 02-R, and 03-R) had venous outflow with a combination of the uterine veins and the utero-ovarian veins, whereas for recipients 04-R and 05-R, the venous outflow was via the utero-ovarian veins. The decision about which of the two vein types to use was made on the back table after assessment of vein wall quality and vein size.
Outcomes: Of these five uterus transplants, the first three failed. A graft hysterectomy was required on postoperative days 14, 12, and 6 for recipients 01-R, 02-R, and 03-R, respectively. In all three patients, the protocol intravaginal Doppler ultrasound showed blood flow in the uterine arteries and veins, although the visual appearance of the cervix was abnormal. In recipients 01-R and 03-R, the transplanted cervix of the uterus appeared congested, whereas in recipient 02-R, the cervix appeared ischemic. In these first three recipients, the protocol biopsy on day 5 showed sloughing of the mucosa and areas of necrosis mixed with viable cells, which had evolved to predominantly necrosis by the second protocol biopsy on day 10 in recipients 01-R and 02-R. These biopsy results prompted an examination under anesthesia and subsequent MRI that confirmed graft necrosis (Figure 3 ), leading to a graft hysterectomy. For the recipient 03-R, the initial day 5 protocol biopsy demonstrating necrosis immediately led to an MRI, which identified findings similar to those seen in recipients 01-R and 02-R; a decision was made to perform a graft hysterectomy without waiting for the second protocol biopsy.
The explant pathology in recipients 01-R and 03-R demonstrated necrotic hemorrhagic damage suggestive of outflow problems (paralleling the congested appearance of the cervix on examination). The explant pathology of recipient 02-R showed ischemic necrosis (paralleling the ischemic appearance of the cervix on examination). Of note, none of the recipients experienced any fever or systemic signs of graft necrosis besides mild elevation of the white blood cell count in one recipient. The protocol biopsies for recipients 04-R and 05-R showed no acute cellular rejection, according to the rejection scheme proposed by the University of Gothenburg (7). The first menstrual period occurred at day 39 for 04-R and day 31 for 05-R, and neither required hormonal stimulation.
Observations and lessons learned: Vein anastomosis: Both vein wall quality and size were relevant for recipients 01-R and 03-R because the thin walls made the anastomosis challenging, despite using a 7-0 Prolene suture. To mitigate the difficulty imposed by these thin venous walls, donor procurement was modified for subsequent cases, taking a patch of internal iliac vein along with the uterine vein. In addition, the venotomy position was moved from the superior aspect of the recipient external iliac vein to the medial aspect, once it was recognized during the first two cases that a downward kinking of the vein occurred when the uterus was pulled caudally and sewn in place. In addition, the venotomy orifice was widened to alleviate this kink. Arterial anastomosis: The arterial anastomosis was constructed using either a patch from or the entire segment of the donor internal iliac artery. In some patients, soft plaque in the area surrounding the takeoff of the uterine artery can complicate the artery or patch, so care must be taken to avoid a dissection. Using the segment of internal iliac artery proximal to the takeoff of the uterine artery allows an easier arterial anastomosis with a larger lumen that was free of plaque.
Uterine cervix: In the first recipient, there was a significant mismatch from the large uterine cervix size compared with the small vaginal vault. This discrepancy made the vaginal anastomosis particularly difficult, and the limited space may have augmented the graft congestion that led to graft failure.
Follow-up: Although arterial and venous Doppler flow was seen in all recipients, using intravaginal Doppler ultrasound, only the successful fourth and fifth recipients had flow seen within the body of the uterus. A disconcerting contradiction exists because these ultrasound Doppler flows that were seen in the first three recipients did not correlate to the appearance of the cervix on the fifth postoperative day. If the ultrasound does not show perfusion within the body of the uterus, if the cervix appears compromised on examination, or if the biopsy shows signs of necrosis, an MRI or direct surgical exploration may be warranted to avoid delay in recognizing graft necrosis from vascular complications.
Discussion
The negative outcomes suffered at the beginning of our experience with living donor uterus transplantation prompted an in-depth analysis of each case. The analysis focused on every aspect of the donor and recipient clinical course, from evaluation to discharge. The observations made and the conclusions reached form the core of this paper. These conclusions are neither final nor absolute. They should be seen as evolutionary steps in the implementation of a new procedure. These conclusions lack any statistical support and may be considered speculative. Nonetheless, the analysis we made was beneficial for our patients, and the last two recipients have been complication-free with a functioning uterus. In this primordial phase, we believe that each uterus transplant needs to be evaluated in isolation and that sharing positive and negative outcomes represents a valid strategy to allow a less steep learning curve.
Many observations have surfaced as potentially significant factors in explaining the improved results after the initial failures.
The fact that some of the uteri had significant vascular pathology made us revisit the age limit for the donors, and we now favor younger donors. The hypothesis is that age-related vascular pathology has an impact on immediate outcome and might have an impact on function. None of the preoperative tests we performed for our donors suggested the presence of extra-or intrauterine vascular pathology. Had a similar amount of disease been seen in a comparable kidney transplant allograft, we would have discarded it. Nonetheless, the real clinical implication of these arterial findings in the uterus is unknown, and very little literature is available on the subject (8) . In fact, the Swedish group successfully used donors aged >60 years. The oldest donor in our series (02-D, age 55 years) had a nearly completely occluded arterial lumen, and even the youngest donor had clear signs of angiopathy. It is possible that a routine backtable uterine biopsy, particularly in older donors or in allografts with small vessels, might identify those uterus allografts with arterial disease that might jeopardize the chances of a successful transplant. Performing a backtable biopsy should not significantly increase the risk for the recipient. Another important point of discussion is how to proceed if a uterus is found to have significant arterial pathology on the back-table inspection, as happened with our donor 02-D. In such cases, the question should be raised whether it is appropriate to continue with the implantation. We have modified our preoperative donor and recipient consent forms to reflect this possibility.
We encountered significant difficulties in performing a proper venous anastomosis, partly because of very thin venous walls and partly because of small size of the veins. One conclusion of our analysis was that in recipients 01-R and 03-R, the venous outflow was responsible for the failure of the grafts. The first inflow and outflow of the first three donors' uteri were studied only by CT angiography (CTA). Strictly from an imaging point of view, CTA accurately characterized donor uterine arteries. Although the utilization of CTA has not been researched explicitly in uterine donator evaluation per se, the superior spatial resolution of CTA affords evaluation of the typically diminutive uterine arteries, with a diameter of 1-2 mm. The ability of CTA to adequately evaluate the uterine arteries was initially inferred from studies using CTA for evaluation of inferior epigastric perforating arteries before free flap reconstruction, as the inferior epigastric perforators are of similar caliber to the uterine arteries (9) . This inference has been validated in a subsequent study of preoperative CTA evaluation of the uterine artery in patients with cervical cancer (10) . Evaluation of uterine veins in our experience found CTA to be insufficient for defining the venous relationships among the uterus, ovary, and gonadal vessels. Although the vein may appear acceptable near the uterine body on CT, it may taper to a group of threadlike tributaries near the internal iliac vein confluence. In hindsight, MRI with venous phase improves the evaluation of the uterine veins, given the superior contrast resolution that MRI affords. The utility of MRI in this regard was initially established in the evaluation of cerebral sinovenous thrombosis and subsequently in the setting of pelvic venous congestion (11) (12) (13) (14) . The better venous mapping obtained with the MRI made the hysterectomies in the last two donors more efficient. Knowing the poor quality of the uterine vein, we avoided lengthy dissection around these vessels and focused on the better utero-ovarian veins; however, neither CTA nor MRI provide information regarding the quality of the uterine vein wall, which routinely was very thin and prone to laceration despite using small sutures and needles. To mitigate this, we extended the dissection of the uterine vein to include a larger portion of the internal iliac vein. This maneuver allows the placement of a curved vascular clamp on the internal iliac vein and yields a uterine vein with a patch of the donor internal iliac vein that has a much stronger, thicker wall.
Another observation specifically in recipient 03-R was that once the uterus had been sewn to the vaginal cuff, a slight kink of the venous outflow at its anastomosis with the iliac vein could be detected. We attributed the kink to the spatial orientation of the uterine vein in relation to the iliac vein. In the first three cases, the anastomosis was performed as in renal transplantation, making a longitudinal venotomy on the superior wall of the iliac vein. In the last two cases, the venotomy was performed more toward the medial wall of the iliac vein, allowing a more natural course for the outflow. Moreover, with the intent of maximizing outflow, we resected a portion of the iliac vein wall to create an oval orifice instead of a simple slit.
Regarding graft congestion, one last observation relates to the size of the donor cervix. It is possible that the large cervix, >4 cm, besides making the anastomosis particularly cumbersome, may have contributed to graft congestion from compression. A proper evaluation of the donor uterus size may be an additional element in avoiding poor outcomes.
The last two recipients have had a flawless postoperative course, and Doppler ultrasound shows consistently excellent venous blood outflow. It is still to be seen whether outflow based solely on the utero-ovarian veins is sufficient during pregnancy.
Taking in consideration the vascular complications that we encountered and in view of the complexity of the microvasculature and low flow state within the uterus, we added a therapeutic regimen of anticoagulation with heparin to be started immediately after surgery (a decision based on the beneficial experience with anticoagulation in the small vasculature of pediatric liver transplants).
Delayed diagnosis of uterus necrosis was a major concern in the patients with failed allografts. The physical symptoms and systemic signs of necrosis were absent, except in one of the recipients, who had a mildly elevated white blood cell count. Doppler flow in the uterine arteries and veins can be false positive and did not identify graft thrombosis in the three failed recipients. It has been our experience that transabdominal is superior to transvaginal Doppler ultrasound, and that has become our test of choice. Nonetheless, if no flow is seen in the parenchyma of the graft, an immediate examination under anesthesia or an MRI is indicated.
Although uterus transplantation is in its infancy, the growing field should ultimately achieve success, similar to what has occurred in all other types of organ transplantation. The key to that success is effective communication of the techniques, pitfalls, and outcomes to the community at large, which allows others to build on that experience and avoid failures. It is our hope that this analysis will achieve this goal and spark innovation by others.
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